- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01892631
Text Messaging Reminders for Influenza Vaccine in Primary Care (TXT4FLUJAB)
A Feasibility Study for a Cluster Randomised Trial of Text Messaging Reminders for Influenza Vaccine in Patients Under 65 in Clinical Risk Groups in English Primary Care.
Influenza morbidity and mortality cause a substantial financial burden to the NHS and to the UK as a whole. Influenza vaccine is safe and effective but is required annually because the circulating strain of virus changes each year. In the UK in 2012, the Chief Medical Officer (CMO) recommended that at least 75% of elderly people (aged 65+) and 75% people under 65 with certain chronic conditions (e.g. chronic heart disease, diabetes, asthma, etc) should be vaccinated. While primary care practices are achieving these targets for elderly patients, those set for younger patients with chronic conditions are not being met, with a third of patients being missed in the 2011/12 flu season and with no substantial improvements in uptake in the past decade. Therefore strategies to increase flu vaccine uptake in these patients are required.
Previous trials have shown that patient reminders can increase vaccine uptake and in particular, text messaging has shown to work in some populations in the United States as a cheap, simple and effective reminder. However, whether the same is true in UK general practice is unclear. The use of text messaging in the NHS for appointment reminders is also increasing as it is cheap, quick and effective. Text messaging is already used in roughly 30% of practices to remind patients about their flu vaccine but there has been no trial addressing its effectiveness. Therefore, we propose a trial of a text messaging flu vaccine reminder in patients aged under 65 who have a chronic condition. We hypothesise that practices that send a text message will have increased flu vaccine uptake.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Select county
-
London, Select county, Vereinigtes Königreich, WC1E 7HT
- London School of Hygiene and Tropical Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- practices must use text messaging software to communicate with patients;
- practices must not have used a text message to remind patients aged under 65 about influenza vaccine in the 2012/13 influenza season.
- practices will send the text message to eligible patients who are aged between 18 and 65, with one of the following risk conditions: chronic respiratory disease, chronic liver disease, chronic kidney disease, chronic heart disease, chronic neurological disease, immunosuppression
Exclusion Criteria:
- practices will not send the text message to pregnant women.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Sonstiges: Standard care
Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
|
Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
|
Experimental: Text messaging intervention
Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
|
Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Proportion of patients at risk who received flu vaccine
Zeitfenster: up to 9 months
|
up to 9 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of practices reporting 'yes' to difficulties
Zeitfenster: up to 3 months
|
Proportion of practices reporting 'yes' that they had difficulties in sending the text message to patients
|
up to 3 months
|
Recruitment rate
Zeitfenster: 3 months after initial contact
|
This is a pilot feasibility study and recruitment of practices to the trial is an outcome.
|
3 months after initial contact
|
Practice delivery of text message
Zeitfenster: One month after study start (October 1st 2013)
|
Did the practice send the text message to eligible patients and was the content of the message as described in the protocol.
|
One month after study start (October 1st 2013)
|
Were outcome data available
Zeitfenster: up to 9 months
|
Were outcome data regarding text message and flu vaccine uptake available.
|
up to 9 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- txt4flujab
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Standard care
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekrutierungPlasmazell-Leukämie | Rezidiviertes/refraktäres multiples MyelomChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy,...RekrutierungChronischer lymphatischer Leukämie | Non-Hodgkin-Lymphom | Akute lymphatische LeukämieVereinigte Staaten
-
Nexcella Inc.Noch keine RekrutierungLeichtketten (AL)-AmyloidoseVereinigte Staaten
-
Second Affiliated Hospital, School of Medicine,...RekrutierungRezidiviertes und refraktäres B-Zell-LymphomChina
-
Second Affiliated Hospital, School of Medicine,...Rekrutierung
-
University of California, San FranciscoZurückgezogenLymphom | Leukämie | Plasmazelldyskrasie
-
Hebei Senlang Biotechnology Inc., Ltd.RekrutierungLymphom | Multiples Myelom | Akute lymphatische LeukämieChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy,...ZurückgezogenAkute lymphatische Leukämie | Non-Hodgkin-LymphomVereinigte Staaten
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRekrutierungPlasmazell-Leukämie | Rezidiviertes/refraktäres multiples MyelomChina
-
Southwest Hospital, ChinaUnbekanntLymphom, große B-Zelle, diffusChina